Literature DB >> 8804573

Inhibition of zeta-crystallin by Coumarins: a structure-activity study.

A S Duhaiman1.   

Abstract

A structure-activity study was carried out to determine the important groups of coumarin derivatives in inhibiting the oxidoreductase activity of the camel lens zeta-crystallin. Coumarin, 4-hydroxycoumarin, 7-hydroxy-4-methylcoumarin, dicoumarol, and warfarin were screened for their inhibitory effect on zeta-crystallin activity. The sequence of potency for the inhibitors was dicoumarol > 4-hydroxycoumarin > warfarin > > coumarin. 7-Hydroxy-4-methylcoumarin was ineffective as an inhibitor. Only dicoumarol, 4-hydroxycoumarin, and warfarin were found to inhibit the oxidoreductase activity in micromolar ranges. All tested inhibitors seem to act in reversible and time-independent manner. Concentration causing 50% inhibition of the enzyme activity (IC50 value) was 34 microM for dicoumarol, 76 microM for 4-hydroxycoumarin, and approximately 515 microM for warfarin, while 1 mM coumarin showed less than 10% inhibition. Kinetic analysis revealed inhibition of camel lens zeta-crystallin by coumarin derivatives to occur in a competitive manner with respect to dichlorophenolindophenol (DCIP) as an electron acceptor and uncompetitive manner with respect to NADPH as an electron donor. The Ki values were found to be 16 microM for dicoumarol, 40 microM for 4-hydroxycoumarin, and 220 microM for warfarin. The structure-activity relationship of coumarin derivatives indicates that the phenolic hydroxyl group at the C-4 position in the coumarin skeleton is important for the maximal inhibition.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8804573     DOI: 10.1007/bf01887114

Source DB:  PubMed          Journal:  J Protein Chem        ISSN: 0277-8033


  13 in total

Review 1.  The pharmacology, metabolism, analysis, and applications of coumarin and coumarin-related compounds.

Authors:  D Egan; R O'Kennedy; E Moran; D Cox; E Prosser; R D Thornes
Journal:  Drug Metab Rev       Date:  1990       Impact factor: 4.518

2.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

3.  Molecular cloning and sequencing of zeta-crystallin/quinone reductase cDNA from human liver.

Authors:  P Gonzalez; P V Rao; J S Zigler
Journal:  Biochem Biophys Res Commun       Date:  1993-03-31       Impact factor: 3.575

4.  Studies on the reaction mechanism of DT diaphorase. Action of dead-end inhibitors and effects of phospholipids.

Authors:  P M Hollander; L Ernster
Journal:  Arch Biochem Biophys       Date:  1975-08       Impact factor: 4.013

5.  Prevention of early recurrence of high risk malignant melanoma by coumarin. Irish Melanoma Group.

Authors:  D Thornes; L Daly; G Lynch; H Browne; A Tanner; F Keane; S O'Loughlin; T Corrigan; P Daly; G Edwards
Journal:  Eur J Surg Oncol       Date:  1989-10       Impact factor: 4.424

Review 6.  Clinically significant drug interactions with the oral anticoagulants.

Authors:  M D Freedman; A G Olatidoye
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

7.  Zeta-crystallin, a novel lens protein from the guinea pig.

Authors:  Q L Huang; P Russell; S H Stone; J S Zigler
Journal:  Curr Eye Res       Date:  1987-05       Impact factor: 2.424

8.  Dicoumarol-sensitive NADPH: phenanthrenequinone oxidoreductase in channel catfish (Ictalurus punctatus).

Authors:  B M Hasspieler; R T Di Giulio
Journal:  Toxicol Appl Pharmacol       Date:  1994-04       Impact factor: 4.219

9.  zeta-Crystallin is a major protein in the lens of Camelus dromedarius.

Authors:  D Garland; P V Rao; A Del Corso; U Mura; J S Zigler
Journal:  Arch Biochem Biophys       Date:  1991-02-15       Impact factor: 4.013

10.  Purification and characterization of zeta-crystallin from the camel lens.

Authors:  A S Duhaiman; N Rabbani; A A AlJafari; A S Alhomida
Journal:  Biochem Biophys Res Commun       Date:  1995-10-13       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.